The cardiovascular pharmacology of COX-2 inhibition
Fries S, Grosser T (2005)
Hematology Am Soc Hematol Educ Program 2005(1): 445-451.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Fries, S;
Grosser, TiloUniBi ![](https://pub.uni-bielefeld.de/images/icon_orcid.png)
![](https://pub.uni-bielefeld.de/images/icon_orcid.png)
Abstract / Bemerkung
Selective inhibitors of cyclooxygenase (COX)-2, the coxibs, were developed to inhibit inflammatory prostaglandins derived from COX-2, while sparing gastroprotective prostaglandins primarily formed by COX-1. However, COX-2-derived prostaglandins mediate not only pain and inflammation but also affect vascular function, the regulation of hemostasis/ thrombosis, and blood pressure control. All coxibs depress COX-2-dependent prostacyclin (PGI2) biosynthesis without effective suppression of platelet COX-1-derived thromboxane (Tx) A2, unlike aspirin or traditional nonsteroidal anti-inflammatory drugs, which inhibit both COX-1 and COX-2. The actions of PGI2 oppose mediators, which stimulate platelets, elevate blood pressure, and accelerate atherogenesis, including TxA2. Indeed, structurally distinct inhibitors of COX-2 have increased the likelihood of hypertension, myocardial infarction and stroke in controlled clinical trials. The detection of these events in patients is related to the duration of exposure and to their baseline risk of cardiovascular disease. Thus, coxibs should be withheld from patients with preexisting cardiovascular risk factors, and exposed patients at low cardiovascular baseline risk should be monitored for changes in their risk factor profile, such as increases in arterial blood pressure.
Erscheinungsjahr
2005
Zeitschriftentitel
Hematology Am Soc Hematol Educ Program
Band
2005
Ausgabe
1
Seite(n)
445-451
ISSN
1520-4391, 1520-4383
Page URI
https://pub.uni-bielefeld.de/record/2965350
Zitieren
Fries S, Grosser T. The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program. 2005;2005(1):445-451.
Fries, S., & Grosser, T. (2005). The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program, 2005(1), 445-451. https://doi.org/10.1182/asheducation-2005.1.445
Fries, S, and Grosser, Tilo. 2005. “The cardiovascular pharmacology of COX-2 inhibition”. Hematology Am Soc Hematol Educ Program 2005 (1): 445-451.
Fries, S., and Grosser, T. (2005). The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program 2005, 445-451.
Fries, S., & Grosser, T., 2005. The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program, 2005(1), p 445-451.
S. Fries and T. Grosser, “The cardiovascular pharmacology of COX-2 inhibition”, Hematology Am Soc Hematol Educ Program, vol. 2005, 2005, pp. 445-451.
Fries, S., Grosser, T.: The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program. 2005, 445-451 (2005).
Fries, S, and Grosser, Tilo. “The cardiovascular pharmacology of COX-2 inhibition”. Hematology Am Soc Hematol Educ Program 2005.1 (2005): 445-451.
Daten bereitgestellt von European Bioinformatics Institute (EBI)
Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
References
Daten bereitgestellt von Europe PubMed Central.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Quellen
PMID: 16304418
PubMed | Europe PMC
Suchen in